“That is superb information. My general feeling was reduction — it’s been an extended path,” mentioned Annaliesa Anderson, the chief scientific officer of Pfizer’s bacterial vaccines and hospital medication division, who leads this system to develop the drug. Anderson, who has been engaged on the drugs since January 2020, mentioned it was a “heart-in-your-mouth second” when she discovered the information Wednesday evening whereas driving to Massachusetts to tour schools.
Discussion about this post